MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor plays a key role in maintaining genomic stability and protection against malignant transformation. MDM2 and MDMX are both p53-binding proteins that regulate p53 stability and activity. Recent development of the MDM2 inhibitor Nutlin 3 has greatly facilitated functional analysis of MDM2-p53 binding. We found that although MDMX is homologous to MDM2 and binds to the same region on p53 N terminus, Nutlin does not disrupt p53-MDMX interaction. The ability of Nutlin to activate p53 is compromised in tumor cells overexpressing MDMX. Combination of Nutlin with MDMX siRNA resulted in synergistic activation of p53 and growth arrest. These results suggest that MDMX is also a valid target for p53 activation in tumor cells. Development of novel compounds that are MDMX-specific or optimized for dual-inhibition of MDM2 and MDMX are necessary to achieve full activation of p53 in tumor cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IC50s reported in this study are consistent with previous reports showing that MDM2 amplified cancer cell lines (e.g. liposarcoma and osteosarcoma lines) are more sensitive to RG7112 or Nutlin-3 [25–28].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [28]
In the citing paper
“Although nutlin 3a and MI-219 robustly activate p53 in cancer cells with overexpressed MDM2, they do not consistently elicit p53-dependent effects in cancer cells that overexpress MDMX99–102.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [101]
Citations
Cites
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
MDMX: a novel p53‐binding protein with some functional properties of MDM2.
Shvarts, A., Steegenga, W. T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., van Ham, R. C., van der Houven van Oordt, W., Hateboer, G., van der Eb, A. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00919.x · Cited by 648
Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., & Lozano, G. (2001) · Nature Genetics · doi:10.1038/ng714 · Cited by 517
HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53
Linares, L. K., Hengstermann, A., Ciechanover, A., Müller, S., & Scheffner, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2030930100 · Cited by 361
MDM2 interacts with MDMX through their RING finger domains
Tanimura, S., Ohtsuka, S., Mitsui, K., Shirouzu, K., Yoshimura, A., & Ohtsubo, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00254-9 · Cited by 324
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310
MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Bond, G., Hu, W., & Levine, A. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 308
Stabilization of the MDM2 Oncoprotein by Interaction with the Structurally Related MDMX Protein
Sharp, D. A., Kratowicz, S. A., Sank, M. J., & George, D. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.53.38189 · Cited by 286
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics
Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271
Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53
Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., & Yuan, Z.-M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200150200 · Cited by 265
Research works printed but not linked: 2
- Ramos, 2001, Cancer Res., 61, 1839
- Bottger, 1996, Oncogene, 13, 2141
Cited by
Items 101–200 of 265
Zanjirband, M., Curtin, N., Edmondson, R. J., & Lunec, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19266 · Cited by 44
The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Puszyński, K., Gandolfi, A., & d’Onofrio, A. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003991 · Cited by 44
Spinnler, C., Hedström, E., Li, H., de Lange, J., Nikulenkov, F., Teunisse, A. F. A. S., Vries, M. V., Grinkevich, V. V., Jochemsen, A. G., & Selivanova, G. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.45 · Cited by 44
Merkel, C. A., Soares, R. B. D. S., de Carvalho, A. C. V., Zanatta, D. B., Bajgelman, M. C., Fratini, P., Costanzi-Strauss, E., & Strauss, B. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-316 · Cited by 43
Targeting Mdmx to treat breast cancers with wild-type p53
Haupt, S., Buckley, D., Pang, J.-M., Panimaya, J., Paul, P. J., Gamell, C., Takano, E. A., Lee, Y. Y., Hiddingh, S., Rogers, T.-M., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.173 · Cited by 43
Smith, J. M., Frost, J. R., & Fasan, R. (2014) · Chemical Communications · doi:10.1039/c4cc01199f · Cited by 42
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma
Hüllein, J., Slabicki, M. M., Rosołowski, M., Jethwa, A., Habringer, S., Tomska, K., Kurilov, R., Lu, J., Scheinost, S., Wagener, R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3438 · Cited by 41
CARPs enhance p53 turnover by degrading 14-3-3σ and stabilizing MDM2
Yang, W., Dicker, D. T., Chen, J., & El‐Deiry, W. S. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5701 · Cited by 40
Self-citationElSawy, K. M., Verma, C. S., Joseph, T. L., Lane, D. P., Twarock, R., & Caves, L. S. D. (2013) · Cell Cycle · doi:10.4161/cc.23511 · Cited by 39
Haaland, I., Opsahl, J. A., Berven, F. S., Reikvam, H., Fredly, H., Haugse, R., Thiede, B., McCormack, E., Laín, S., Bruserud, Ø., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-116 · Cited by 38
Hiss, D. C., & Gabriels, G. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903052559 · Cited by 37
Inhibitors of MDM2 and MDMX: A Structural Perspective
Riedinger, C., & McDonnell, J. M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.75 · Cited by 37
Dudgeon, D. D., Shinde, S. N., Shun, T. Y., Lazo, J. S., Strock, C. J., Giuliano, K. A., Taylor, D. L., Johnston, P. A., & Johnston, P. A. (2010) · Assay and Drug Development Technologies · doi:10.1089/adt.2010.0281 · Cited by 37
Dudgeon, D. D., Shinde, S. S., Hua, Y., Shun, T. Y., Lazo, J. S., Strock, C. J., Giuliano, K. A., Taylor, D. L., Johnston, P. A., & Johnston, P. A. (2010) · SLAS DISCOVERY · doi:10.1177/1087057110375304 · Cited by 37
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia
Tan, B. X., Khoo, K. H., Lim, T. M., & Lane, D. P. (2013) · Oncotarget · doi:10.18632/oncotarget.1559 · Cited by 36
Fan, Y., Li, M., Ma, K., Hu, Y., Jing, J., Shi, Y., Li, E., & Dong, D. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1539290 · Cited by 34
Distinct Roles of MDMX in the Regulation of p53 Response to Ribosomal Stress
Gilkes, D. M., & Chen, J. (2007) · Cell Cycle · doi:10.4161/cc.6.2.3719 · Cited by 34
Self-citationNutlin-3 Affects Expression and Function of Retinoblastoma Protein
Du, W., Wu, J., Walsh, E. M., Zhang, Y., Chen, C. Y., & Xiao, Z.-X. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046904 · Cited by 33
E2F1-dependent oncogenic addiction of melanoma cells to MDM2
Verhaegen, M. E., Chęcińska, A., Riblett, M., Wang, S., & Soengas, M. S. (2011) · Oncogene · doi:10.1038/onc.2011.277 · Cited by 33
Macchiarulo, A., Giacchè, N., Carotti, A., Baroni, M., Cruciani, G., & Pellicciari, R. (2008) · Journal of Chemical Information and Modeling · doi:10.1021/ci800146m · Cited by 33
Zheng, M., Yang, J., Xu, X., Sebolt, J. T., Wang, S., & Sun, Y. (2010) · PubMed · Cited by 33
Stochastic Modeling and Simulation of the p53-MDM2/MDMX Loop
Cai, X., & Yuan, Z.-M. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.0231 · Cited by 34
Abnormal MDMX degradation in tumor cells due to ARF deficiency
Li, X., Gilkes, D., Li, B., Cheng, Q., Pernazza, D., Lawrence, H., Lawrence, N., & Chen, J. (2012) · Oncogene · doi:10.1038/onc.2011.534 · Cited by 32
“However, several reports found that Nutlin treatment does not cause significant reduction in the MDMX level in tumor cell lines, and may even increase the MDMX level in certain cell lines due to p53-mediated induction of MDMX transcription (Hu et al., 2006; Wade et al., 2006; Li et al., 2010).”
InfluentialSelf-citationRPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4
Weinstein, H. N. W., Hu, K., Fish, L., Chen, Y.-A., Allegakoen, P., Pham, J. H., Hui, K. S. F., Chang, C., Tutar, M., Benitez-Rivera, L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114622 · Cited by 32
Rieber, M., & Strasberg-Rieber, M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.003 · Cited by 30
Novel isatin-derived molecules activate p53 via interference with Mdm2 to promote apoptosis
Fedorova, O., Daks, A. A., Petrova, V., Petukhov, A., Lezina, L., Shuvalov, O. Y., Davidovich, P. B., Kriger, D. V., Lomert, E. V., Tentler, D., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1506664 · Cited by 31
Biderman, L., Poyurovsky, M. V., Assia, Y., Manley, J. L., & Prives, C. L. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06150-11 · Cited by 30
Palani, C. D., Beck, J. F., & Sonnemann, J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9510-7 · Cited by 30
MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present)
Rusiecki, R., Witkowski, J., & Jaszczewska‐Adamczak, J. A. (2019) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892814666191022163540 · Cited by 30
Structure and function of MDM2 and MDM4 in health and disease
Zhu, I. Y., Lloyd, A., Critchley, W. R., Saikia, Q., Jade, D., Divan, A., Zeqiraj, E., Harrison, M. A., Brown, C. J., & Ponnambalam, S. (2025) · Biochemical Journal · doi:10.1042/bcj20240757 · Cited by 29
In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
Wei, S. J., Joseph, T., Sim, A. Y. L., Yurlova, L., Zolghadr, K., Lane, D., Verma, C., & Ghadessy, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062564 · Cited by 28
Natarajan, U., Venkatesan, T., Radhakrishnan, V., Samuel, S., Rasappan, P., & Rathinavelu, A. (2019) · Medicina · doi:10.3390/medicina55020030 · Cited by 29
Kan, C. E., Patton, J. T., Stark, G. R., & Jackson, M. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0259 · Cited by 29
Bo, M. D., Secchiero, P., Degan, M., Marconi, D., Bomben, R., Pozzato, G., Gaïdano, G., Poeta, G. D., Forconi, F., Zauli, G., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08185.x · Cited by 29
Chen, J., Zhang, D., Zhang, Y., & Li, G. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13022176 · Cited by 28
Self-citationMerlino, F., Daniele, S., Pietra, V. L., Maro, S. D., Leva, F. S. D., Brancaccio, D., Tomassi, S., Giuntini, S., Cerofolini, L., Fragai, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00004 · Cited by 28
Imanishi, M., Yamamoto, Y., Wang, X., Sugaya, A., Hirose, M., Endo, S., Natori, Y., Yamato, K., & Hyodo, I. (2018) · Cancer Science · doi:10.1111/cas.13893 · Cited by 27
Calculation of hot spots for protein–protein interaction in p53/PMI‐MDM2/MDMX complexes
Huang, D., Qi, Y., Song, J., & Zhang, J. Z. H. (2018) · Journal of Computational Chemistry · doi:10.1002/jcc.25592 · Cited by 27
MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Wu, J., Lu, G., & Wang, X. (2021) · PubMed Central · Cited by 26
Heminger, K., Markey, M. P., Mpagi, M. D., & Berberich, S. J. (2009) · Aging · doi:10.18632/aging.100008 · Cited by 25
Giustiniano, M., Daniele, S., Pelliccia, S., Pietra, V. L., Pietrobono, D., Brancaccio, D., Cosconati, S., Messere, A., Giuntini, S., Cerofolini, L., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00912 · Cited by 25
Drummond, C. J., Esfandiari, A., Liu, J., Lü, X., Hutton, C., Jackson, J., Bennaceur, K., Xu, Q., Makimanejavali, A. R., Bello, F. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10073 · Cited by 24
Isaac, R., Goldstein, I., Furth, N., Zilber, N., Streim, S., Boura‐Halfon, S., Elhanany, E., Rotter, V., Oren, M., & Zick, Y. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.108 · Cited by 24
Philippe, G. J.-B., Mittermeier, A., Lawrence, N., Huang, Y., Condon, N. D., Loewer, A., Craik, D. J., & Henriques, S. T. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00988 · Cited by 24
Philippe, G. J.-B., Gaspar, D., Sheng, C., Huang, Y., Benfield, A. H., Condon, N. D., Weidmann, J., Lawrence, N., Loewer, A., Castanho, M. A. R. B., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00593 · Cited by 24
Noncanonical roles of p53 in cancer stemness and their implications in sarcomas
Curylova, L., Ramos, H., Saraiva, L., & Skoda, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.037 · Cited by 23
Bozzi, F., Conca, E., Laurini, E., Posocco, P., Sardo, A. L., Jocollé, G., Sanfilippo, R. G., Gronchi, A., Perrone, F., Tamborini, E., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.107 · Cited by 22
Tsuganezawa, K., Nakagawa, Y., Kato, M., Taruya, S., Takahashi, F., Endoh, M., Utata, R., Mori, M., Ogawa, N., Honma, T., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112460729 · Cited by 21
Oduah, E., & Grossman, S. R. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1702403 · Cited by 21
Fan, Y., Ma, K., Jing, J., Wang, C., Hu, Y., Shi, Y., Li, E., & Geng, Q. (2019) · Journal of Cancer · doi:10.7150/jca.32765 · Cited by 20
Cipriano, R., Patton, J. T., Mayo, L. D., & Jackson, M. W. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11193 · Cited by 20
Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53
Karan, G., Wang, H., Chakrabarti, A., Karan, S., Liu, Z., Xia, Z., Gundluru, M., Moreton, S. A., Saunthararajah, Y., Jackson, M. W., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0467 · Cited by 20
Han, X., Medeiros, L. J., Zhang, Y. H., You, M. J., Andreeff, M., Konopleva, M. Y., & Bueso-Ramos, C. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.03.012 · Cited by 20
Imidazoline derivatives: a patent review (2006 – present)
Guan, X., & Hu, Y. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.727397 · Cited by 19
MDM2 oligomers: antagonizers of the guardian of the genome
Leslie, P. L., & Zhang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.88 · Cited by 19
Chemical Instability and Promiscuity of Arylmethylidenepyrazolinone-Based MDMX Inhibitors
Stefaniak, J., Lewis, A. M., Conole, D., Galan, S. R. G., Bataille, C. J. R., Wynne, G. M., Castaldi, M. P., Lundbäck, T., Russell, A. J., & Huber, K. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00665 · Cited by 19
Lehmann, B. D., McCubrey, J. A., & Terrian, D. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4544 · Cited by 19
GENG, Q.-Q., DONG, D.-F., CHEN, N.-Z., WU, Y.-Y., Li, E. X., Wang, J., & Wang, S. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2138 · Cited by 18
Discovery of new low-molecular-weight p53–Mdmx disruptors and their anti-cancer activities
Uesato, S., Matsuura, Y., Matsue, S., Sumiyoshi, T., Hirata, Y., Takemoto, S., Kawaratani, Y., Yamai, Y., Ishida, K., Sasaki, T., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.03.021 · Cited by 17
Lenos, K., de Lange, J., Teunisse, A. F., Lodder, K., Verlaan-de Vries, M., Wiercinska, E., van der Burg, M. J., Szuhai, K., & Jochemsen, A. G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-111 · Cited by 16
Mdm2 requires Sprouty4 to regulate focal adhesion formation and metastasis independent of p53
de Queiroz, R. M., Efe, G., Guzman, A., Hashimoto, N., Kawashima, Y., Tanaka, T., Rustgi, A. K., & Prives, C. L. (2024) · Nature Communications · doi:10.1038/s41467-024-51488-2 · Cited by 16
Xie, X., He, G., & Siddik, Z. H. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.117564 · Cited by 16
Rasafar, N., Barzegar, A., & Aghdam, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-67510-8 · Cited by 16
Hirose, M., Yamato, K., Endo, S., Saito, R., Ueno, T., Hirai, S., Suzuki, H., Abei, M., Natori, Y., & Hyodo, I. (2014) · Oncoscience · doi:10.18632/oncoscience.103 · Cited by 16
Predicted Functions of MdmX in Fine-Tuning the Response of p53 to DNA Damage
Kim, S., Aladjem, M. I., McFadden, G. B., & Kohn, K. W. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000665 · Cited by 16
Lama, R., Xu, C., Galster, S. L., Querol-García, J., Portwood, S. M., Mavis, C. K., Ruiz, F. M., Martin, D. L., Wu, J., Giorgi, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933446 · Cited by 15
Joshi, M. R., Yao, N., Myers, K. A., & Li, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080926 · Cited by 15
Analysis and Design of Piezoelectric Braille Display
Smithmaitrie, P. (2009) · InTech eBooks · doi:10.5772/7391 · Cited by 15
Carotti, A., Macchiarulo, A., Giacchè, N., & Pellicciari, R. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22464 · Cited by 14
MDM4 overexpression contributes to synoviocyte proliferation in patients with rheumatoid arthritis
Xu, N., Wang, Y., Li, D., Chen, G., Sun, R., Zhu, R., Sun, S., Liu, H., Yang, G., & Dong, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.069 · Cited by 14
Structure of Human MDM4 N-Terminal Domain Bound to a Single-Domain Antibody
Yu, G. W., Vaysburd, M., Allen, M. D., Settanni, G., & Fersht, A. R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.11.043 · Cited by 14
MDM2/MDMX inhibitor peptide: WO2008106507
Macchiarulo, A., & Pellicciari, R. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902755137 · Cited by 13
Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 12
Nutlin3a-Loaded Nanoparticles Show Enhanced Apoptotic Activity on Prostate Cancer Cells
BÜTÜNER, B. D., Kotmakçı, M., Öner, E., Özduman, G., & Kantarcı, A. G. (2019) · Molecular Biotechnology · doi:10.1007/s12033-019-00178-2 · Cited by 12
Mdm2 and MdmX Involvement in Human Cancer
Berberich, S. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_15 · Cited by 12
Liu, S., Geng, Y.-Z., & Yan, S. (2017) · Frontiers of Physics · doi:10.1007/s11467-017-0667-9 · Cited by 12
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12
Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 12
Natarajan, U., Venkatesan, T., Dhandayuthapani, S., Dondapatti, P., & Rathinavelu, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109742 · Cited by 11
Gα12/13 Basally Regulates p53 through Mdm4 Expression
Kim, M.-S., Lee, S. M., Kim, W., Ki, S. H., Moon, A., Lee, C. H., & Kim, S. G. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0395 · Cited by 11
Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system
Datta, S., Bucks, M. E., Koley, D., Lim, P. X., & Savinov, S. N. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.053 · Cited by 11
Johnson, J. L., Lagowski, J. P., Lawson, S. K., Liu, Y., & Kulesz-Martin, M. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210941 · Cited by 11
Roscoe, I., Parker, M., Dong, D., Li, X., & Li, Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00647 · Cited by 10
Shi, S., Zhang, S., & Zhang, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141409 · Cited by 10
The Landscape of Immunotherapy for Retroperitoneal Sarcoma
Gingrich, A. A., Nassif, E. F., Roland, C. L., & Keung, E. Z.-Y. (2023) · Current Oncology · doi:10.3390/curroncol30020165 · Cited by 9
Valentini, S., Mele, G., Attili, M., Assenza, M. R., Saccoccia, F., Sardina, F., Rinaldo, C., Massari, R., Tirelli, N., Pontecorvi, A., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70006 · Cited by 9
Ribeiro, H. D. O., Cortez, A. P., de Ávila, R. I., da Silva, A. C. G., de Carvalho, F. S., Menegatti, R., Lião, L. M., & Valadares, M. C. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12540 · Cited by 8
Zhao, X., Xiong, D., Luo, S., & Duan, L. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01780f · Cited by 8
Chen, J., Wang, J., Pang, L., & Zhu, W. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13345 · Cited by 7
Self-citationSinatkas, V., Σταθοπούλου, Κ., Xagoraris, I., Ye, J., Vyrla, D., Atsaves, V., Leventaki, V., Medeiros, L. J., Rassidakis, G. Z., & Drakos, E. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1876871 · Cited by 7
Frosi, Y., Inoue, K., Ramlan, S. R., Lane, D. P., Watanabe, T., & Brown, C. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-54123-z · Cited by 7
Jetzt wird es ernst: strukturbasiertes Design von Mdm2/Mdmx‐p53‐Inhibitoren
Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie · doi:10.1002/ange.201003863 · Cited by 7
Lama, R., Galster, S. L., Xu, C., Davison, L. W., Chemler, S. R., & Wang, X. (2022) · Molecules · doi:10.3390/molecules27227665 · Cited by 6
Lama, R., Fose, J. M., Martín, D., Muñoz, I. G., Wang, E. S., Sung, P. J., Chemler, S. R., & Wang, X. (2025) · Molecules · doi:10.3390/molecules30010186 · Cited by 6
Kulp, J. L., Cloudsdale, I. S., Kulp, J. L., & Guarnieri, F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183327 · Cited by 6
Targeting “undruggable” cancer proteins: pharmacological challenges and emerging strategies
Coelho‐Silva, J. L., Parducci, N. S., Carvalho, M. F. L., Vahedian, V., Lima, K., de Almeida, B. O., & Machado‐Neto, J. A. (2026) · Translational Cancer Research · doi:10.21037/tcr-2025-1-2830 · Cited by 5
Virtual Screening for DNA Repair Inhibitors
Barakat, K., & Tuszyński, J. A. (2011) · InTech eBooks · doi:10.5772/24436 · Cited by 5
The evolution of Nutlins as p53-MDM2 inhibitors
Bazanov, D. R., & Lozinskaya, N. A. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03492-4 · Cited by 4
The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer
de Brot, S., & Mongan, N. P. (2017) · Molecular pathology library · doi:10.1007/978-3-319-64096-9_22 · Cited by 4
Avaliação farmacológica e toxicológica de novos candidatos a protótipos de fármacos antitumorais
de Carvalho, F. S. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 4
Metadata
- Authors
- Hu, B., Gilkes, D. M., Farooqi, B., Sebti, S. M., & Chen, J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Chen, Jiandong
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-11
- Volume
- 281
- Issue
- 44
- Pages
- 33030-33035
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2052516738
- Cited by
- 236
- References
- 29
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 10 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 7 · 2016: 17 · 2015: 5 · 2014: 11 · 2013: 14 · 2012: 17
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5082 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDMX, MDM2, p53 activation, Nutlin-3, MDM2 inhibitors, p53 stabilization, tumor suppressor, siRNA knockdown, growth arrest
- MeSH terms
- Cell Line, Humans, Imidazoles, Piperazines, Protein Binding, Tumor Suppressor Protein p53, RNA, Small Interfering, Cell Proliferation, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.